Innovative Neurotherapies Vanqua Bio is focused on developing transformative treatments for neurodegenerative diseases like Parkinson's, Alzheimer's, and ALS, creating opportunities to collaborate on advanced biologics and targeted therapies that align with their proprietary research tools and patient-derived cell models.

Recent Industry Engagement With upcoming presentations at the AD/PD 2026 International Conference in Copenhagen, there is potential for establishing strategic partnerships, licensing deals, or research collaborations with other biotech and pharmaceutical companies attending or involved in this leading neurology forum.

Growing Leadership Team The appointment of Maurizio Facheris as Chief Medical Officer signifies expansion and increased expertise in clinical development, presenting opportunities to offer specialized medical consulting, clinical trial services, or joint research initiatives to support their growth phase.

Pipeline Expansion Launching novel compounds such as the C5aR antagonists indicates an active product pipeline, making them a potential partner or customer for contract research organizations, biotech suppliers, and pharma companies seeking innovative immunology and neurological therapeutics.

Funding and Growth Having secured substantial Series B funding and revenue in the range of $25M to $50M, Vanqua Bio is well-positioned to invest in research collaborations, licensing opportunities, and strategic alliances with suppliers and service providers targeting the neurodegenerative disease market niche.